Friday, July 10, 2026

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati

Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Clinical program

Fianlimab

Phase 2 · small molecule · Advanced Melanoma

Fianlimab for Advanced Melanoma is a Phase 2 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

← All Regeneron UK Limited projects Phase 2 small molecule active

Internal code 24-166

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Regeneron UK Limited
Phase
Phase 2
Modality
small_molecule
Indication
Advanced Melanoma
Status
active
Trials
1

Clinical trials